Immunotherapy strategies targeting MSLN in MPM include the use of chimeric monoclonal antibody (amatuximab), antibody–drug conjugates (anetumab ravtansine, BMS-986148, and BAY2287411), immunotoxins (SS1P and LMB-100), a cancer vaccine (Listeria monocytogenes vaccine expressing MSLN), and CAR T cell immunotherapy (Figure 1B) [89,93]. The gene discussed is MSLN; the disease is cancer.